Tissue analysis for understanding head and neck diseases

  • Research type

    Research Study

  • Full title

    Tissue analysis for stratifying therapy in head and neck diseases

  • IRAS ID

    289677

  • Contact name

    Christian Ottensmeier

  • Contact email

    c.ottensmeier@liverpool.ac.uk

  • Sponsor organisation

    The Clatterbridge Cancer Centre NHS Foundation Trust

  • Duration of Study in the UK

    5 years, 0 months, 0 days

  • Research summary

    Head and Neck cancer is the 6th most common cancer worldwide. Risk factors for Head and Neck cancer include tobacco consumption, alcohol and viral infections such as Human Papilloma Virus.

    In recent years, many diseases have been found to be affected by how the immune system works. There are now new treatments, which target the immune system (immunotherapy). These can be used on their own or together with existing treatments. Promising results have been seen in patients with different types of diseases, including head and neck
    diseases.

    So far only a small number of people benefit from immunotherapy. This is because we still do not fully understand how immunotherapy works and how to choose the right treatment for the right person.

    SARS-CoV-2 is a viral infection causing a global pandemic. It is not clear what factors contribute to the severity of the disease and whether recovery from the acute infection protects against future re-infection. There may be a link between a good anti-cancer immune response and immune response against viral infections.

    We would like to look at blood and tissue samples from patients with head and neck cancer and other non-cancer head and neck diseases. We will establish if these patients have had previous exposure to known viral infections such as SARS-CoV-2 and Human Papilloma Virus to better understand how the immune system works.

    The purpose of this project is to improve our knowledge of how the immune system works in head and neck and viral diseases.

    Our long term aim is that the results will guide us to developing better treatments for a range of diseases including viral infections and cancer.

  • REC name

    South Central - Berkshire Research Ethics Committee

  • REC reference

    20/SC/0406

  • Date of REC Opinion

    23 Nov 2020

  • REC opinion

    Favourable Opinion